{"filing":{"accession_number":"0001104659-26-093390","cik":"0002020932","ticker":"AGMB","company_name":"Agomab Therapeutics NV","form":"6-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"tm2622735d1_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2020932/000110465926093390/tm2622735d1_6k.htm"},"events":[{"id":26616,"run_id":24196,"accession_number":"0001104659-26-093390","anchor_item_number":"EX-99.1","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Agomab Therapeutics announced the proposed appointments of Marino Garcia and Dr. Naimish Patel as non-executive members of the Board of Directors, to be submitted for shareholder approval at a Special General Meeting on September 11, 2026. Both candidates bring significant industry experience in biotechnology leadership and clinical development, directly relevant to the company's strategic direction.","company_name":"Agomab Therapeutics NV","ticker":"AGMB","filing_date":"2026-08-10","form":"6-K","submitted_at":null,"items":[{"id":27804,"accession_number":"0001104659-26-093390","item_number":"EX-99.1","item_title":"tm2622735d1_ex99-1.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The exhibit announces the proposed appointments of Marino Garcia and Dr. Naimish Patel as non-executive members of the Board of Directors, to be submitted for shareholder approval at a Special General Meeting on September 11, 2026. Both candidates bring significant industry experience in biotechnology leadership and clinical development, directly relevant to Agomab's strategy. Board appointments of this caliber are material to investors' assessment of governance and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:28:38.675081+00:00","company_name":"","ticker":null,"filing_date":""},{"id":27805,"accession_number":"0001104659-26-093390","item_number":"EX-99.2","item_title":"tm2622735d1_ex99-2.htm","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"This exhibit is an invitation to a special and extraordinary general shareholders' meeting scheduled for September 11, 2026. The special meeting agenda includes appointment of two non-executive directors (Mr. Marino Garcia and Dr. Naimish Patel), while the extraordinary meeting agenda addresses consolidation and split of Pre-IPO subscription rights following the company's IPO. While director appointments could be classified as `exec_appointment`, the document is primarily a governance notice bundling multiple shareholder-meeting items (director elections and subscription-right adjustments) rather than announcing a discrete executive appointment event. The subscription-right consolidation is a technical capital-structure adjustment necessitated by the prior IPO stock split and is economically neutral. This is best classified as a governance event that does not fit a specific named category.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:28:38.675081+00:00","company_name":"","ticker":null,"filing_date":""},{"id":27806,"accession_number":"0001104659-26-093390","item_number":"EX-99.3","item_title":"tm2622735d1_ex99-3.htm","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"reasoning":"This exhibit is a proxy statement and notice of shareholder meeting for Agomab Therapeutics' special and extraordinary general meeting scheduled for September 11, 2026. The document contains two governance matters: (1) appointment of two non-executive directors (Marino Garcia and Dr. Naimish Patel) to the Board, and (2) a technical consolidation and split of pre-IPO subscription rights to align their exercise mechanics with post-IPO subscription rights. While director appointments would normally be classified as `exec_appointment`, this is a proxy/voting document itself rather than a discrete announcement of the appointment event. The subscription rights adjustment is a routine post-IPO administrative matter designed to be \"neutral from a financial and economic perspective.\" Neither matter would materially affect a reasonable investor's assessment of the company's prospects or financial condition.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:28:38.675081+00:00","company_name":"","ticker":null,"filing_date":""},{"id":27807,"accession_number":"0001104659-26-093390","item_number":"EX-99.4","item_title":"tm2622735d1_ex99-4.htm","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"reasoning":"This exhibit is a voting form (stemformulier) for a special and extraordinary general shareholders' meeting scheduled for September 11, 2026. It contains two governance matters: (1) appointment of two non-executive directors (Marino Garcia and Dr. Naimish Patel) to the Board, and (2) a technical consolidation and split of Pre-IPO subscription rights to align their exercise mechanics with Post-IPO subscription rights following the company's IPO. The director appointments are governance events, but the subscription-rights adjustment is a routine administrative/technical matter explicitly described as \"neutral from a financial and economic perspective.\" The voting form itself is a procedural disclosure, not a discrete event announcement, and the substance—director elections and a technical equity adjustment—does not materially affect investor assessment beyond normal governance processes.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:28:38.675081+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27804,"accession_number":"0001104659-26-093390","item_number":"EX-99.1","item_title":"tm2622735d1_ex99-1.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The exhibit announces the proposed appointments of Marino Garcia and Dr. Naimish Patel as non-executive members of the Board of Directors, to be submitted for shareholder approval at a Special General Meeting on September 11, 2026. Both candidates bring significant industry experience in biotechnology leadership and clinical development, directly relevant to Agomab's strategy. Board appointments of this caliber are material to investors' assessment of governance and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:28:38.675081+00:00","company_name":"Agomab Therapeutics NV","ticker":"AGMB","filing_date":"2026-08-10"},{"id":27805,"accession_number":"0001104659-26-093390","item_number":"EX-99.2","item_title":"tm2622735d1_ex99-2.htm","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"This exhibit is an invitation to a special and extraordinary general shareholders' meeting scheduled for September 11, 2026. The special meeting agenda includes appointment of two non-executive directors (Mr. Marino Garcia and Dr. Naimish Patel), while the extraordinary meeting agenda addresses consolidation and split of Pre-IPO subscription rights following the company's IPO. While director appointments could be classified as `exec_appointment`, the document is primarily a governance notice bundling multiple shareholder-meeting items (director elections and subscription-right adjustments) rather than announcing a discrete executive appointment event. The subscription-right consolidation is a technical capital-structure adjustment necessitated by the prior IPO stock split and is economically neutral. This is best classified as a governance event that does not fit a specific named category.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:28:38.675081+00:00","company_name":"Agomab Therapeutics NV","ticker":"AGMB","filing_date":"2026-08-10"},{"id":27806,"accession_number":"0001104659-26-093390","item_number":"EX-99.3","item_title":"tm2622735d1_ex99-3.htm","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"reasoning":"This exhibit is a proxy statement and notice of shareholder meeting for Agomab Therapeutics' special and extraordinary general meeting scheduled for September 11, 2026. The document contains two governance matters: (1) appointment of two non-executive directors (Marino Garcia and Dr. Naimish Patel) to the Board, and (2) a technical consolidation and split of pre-IPO subscription rights to align their exercise mechanics with post-IPO subscription rights. While director appointments would normally be classified as `exec_appointment`, this is a proxy/voting document itself rather than a discrete announcement of the appointment event. The subscription rights adjustment is a routine post-IPO administrative matter designed to be \"neutral from a financial and economic perspective.\" Neither matter would materially affect a reasonable investor's assessment of the company's prospects or financial condition.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:28:38.675081+00:00","company_name":"Agomab Therapeutics NV","ticker":"AGMB","filing_date":"2026-08-10"},{"id":27807,"accession_number":"0001104659-26-093390","item_number":"EX-99.4","item_title":"tm2622735d1_ex99-4.htm","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"reasoning":"This exhibit is a voting form (stemformulier) for a special and extraordinary general shareholders' meeting scheduled for September 11, 2026. It contains two governance matters: (1) appointment of two non-executive directors (Marino Garcia and Dr. Naimish Patel) to the Board, and (2) a technical consolidation and split of Pre-IPO subscription rights to align their exercise mechanics with Post-IPO subscription rights following the company's IPO. The director appointments are governance events, but the subscription-rights adjustment is a routine administrative/technical matter explicitly described as \"neutral from a financial and economic perspective.\" The voting form itself is a procedural disclosure, not a discrete event announcement, and the substance—director elections and a technical equity adjustment—does not materially affect investor assessment beyond normal governance processes.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:28:38.675081+00:00","company_name":"Agomab Therapeutics NV","ticker":"AGMB","filing_date":"2026-08-10"}]}